Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO

AI Summary

Kelun-Biotech reported updated Phase II results for sacituzumab tirumotecan combined with pembrolizumab in advanced urothelial carcinoma at the 2026 ESMO Congress. The study evaluates the combination as a potential treatment for patients with advanced bladder cancer.

CHENGDU, China, Oct. 24, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, updated results from the Phase II MK-2870-002/SKB264-II-06 study of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) plus MSD’s[1] anti-programmed cell death protein 1 […]